ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Oct. 1, 2008, that it has signed a new, multiyear, firm fixed price contract with the U.S. Department of Health and Human Services to supply an additional 14.5 million doses of BioThrax (Anthrax Vaccine Adsorbed) for inclusion in the Strategic National Stockpile.
The total value of this follow-on contract is between $364 million and $404 million, with the higher amount tied to the delivery of product having a four-year expiration date. First deliveries of BioThrax under this new contract are scheduled to begin in the third quarter of 2009, immediately following the scheduled completion of deliveries under the company’s current $448 million contract to supply 18.75 million doses of BioThrax to the SNS. Final product deliveries under this new contract are anticipated in the third quarter of 2011.
BioThrax is the only vaccine for the prevention of anthrax infection that is licensed by the Food and Drug Administration. It is approved by the FDA as a pre-exposure prophylaxis for use in adults who are at high risk of exposure to anthrax spores. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Baccillus anthracis and contains no dead or live bacteria. BioThrax is administered by subcutaneous injection in three initial doses followed by three additional doses, with an annual booster dose recommended thereafter.
Since 1998, the U.S. government has procured nearly 32 million doses of BioThrax. During that time period, nearly 7.9 million doses have been administered to more than 2 million military personnel.